With the highlights and operating environment, the segments, and then for the first time in this session, you will meet our CFO for the Financial Review. Before we go to the Q&A, if we then start with how quarter three has been going overall, I'm really happy to announce that we have improved the profitability compared to a year ago. The net sales were €424 million, which is up 19%. If we look at organic growth, it's 5%, which is due to a change from consignment stock to inventory stock. In one of the pharmaceutical companies, the adjusted EBIT was €5.5 million, and that's a growth of 25%. Adjusted EBIT, excluding the Svensk dos AB, Sweden, was €5.4 million. The net sales growth was driven by the distribution segment, which is also the reason why profitability has improved. So the net sales growth and the lower freight cost are the reasons for the improvement in profitability. The main reason the refined strategy was launched was one year ago. We announced it during the webcast a year ago, and we can see steady progress towards the goals in the strategy. I will also mention that even though we have seen changes in the management team during the third quarter, the management team is fully committed to the strategy and the long-term goals that we have for the company. A really important part of the refined strategy is the ERP project, which is proceeding according to plan. We have in the quarter renewed and harmonized the processes, and we are now in the end phase of finalizing this project phase. And then, of course, starting the build process in the joint venture company Kronans Apotek, we can see that e-commerce sales were growing by double digits, and that's improving the e-commerce footprint in Sweden. In Sweden, this is really important since we know that the e-commerce segment is very large. In Sweden, it's around 25% of the total pharmacy market. Pharmacy market in the pharmaceutical pharmacies. We can see that the volumes were relatively flat. And that has resulted in flat sales compared to a year ago. Then, going to the operating environment, the overall operating environment has stabilized. We can see that consumer confidence in Sweden is at a more normal level than in Finland, where it's a little bit weaker. The cost inflation, which mainly affects Oriola due to energy and fuel prices, has slowed down and normalized during the quarter. We can also see that this is most likely what will happen in the quarter. Challenges in the availability of pharmaceuticals continue in both Sweden and Finland, as well as in Europe, and this is also something that we predict will continue for the ongoing quarter. The pharmaceutical distribution market is continuing with steady growth, driven mainly by a strong demand in high-value pharmaceuticals. This is a trend that we have seen. And we can also, in this case, see that this is something that will continue in the future. Then, going to our segments. Let's start with the distribution segment. In Finland, we can see a stable market share but a small decline in Sweden. Net sales grew by 23% in this segment to €3,351 million, and that represents a 23% growth. And like I said before, this is because of a customer shifting from consignment stock to inventory stock. And that means that organic growth was 5%. We have higher market volumes and also price increases. That is what is supporting the organic growth. The profitability improved in this segment by 46%, with adjusted EBIT reaching €5 million compared to €3.5 million a year ago. And like I already stated, mainly depending on net sales growth and also lower costs year on year. I'm really pleased to see that we are also now building for the future in this segment. During the quarter, we have signed new and also renewed existing distribution agreements, and that will be visible also for the future quarters to come. And since we have in the strategy that we will work more cross-market, I'm also really pleased to see that we, during the quarter, have signed a cross-market customer with volumes that will start during quarter 1 in 2025. In Sweden, we have entered a new sales channel, and that's the optician channel. And that also provides opportunities for the wholesale segment. Since we have quite a few products in the wholesale segment, there is also a possibility to sell in this new channel. Then going to the wholesale segment.
Wholesale segment is then consisting of the traded goods, the OTC products, the parallel import and the specialized medicines, as well as the advisory services that we then have in Oriola's portfolio. The long-term strategic goal is to grow the wholesale business in this segment. The net sales were flat at €74 million, and the profitability was also at last year's level. We can see that the Finnish wholesale business was stable, but the volumes in Sweden were declining. We are in this segment now, building for the future, and also in this segment I can see that we have added new products and suppliers to the portfolio, something that we will build on for the future. We will also gain new listings. And that means that we have new products coming into the customer portfolio, and we have also introduced new products in the Finnish market. In Sweden, I'm really pleased to see that the Dexal brand has now been introduced, and that's the first time that we can see that we are taking some products from Finland and introducing them to Sweden, and that is then one part really important for the strategic growth in this segment.
A year ago, we also announced that we should sell all shares in Svensk dos AB to Apotekstjänst Sverige AB. We signed that contract in October 2023. And I think all of you also remember that during the spring, we announced that the Swedish Competition Authority had announced that the sale to Apotekstjänst Sverige AB was prohibited due to negative effects on market competition. It has also been announced that Apotekstjänst Sverige AB has appealed this decision, and during the autumn there has been an ongoing process for which we are awaiting the outcome in November. And this means that we will come back to this, of course, when we know more about the outcome. I will also tell you here now that there is one more instance to which you can appeal. So it might be that we will take a little bit longer before we have really finalized this process. Oriola is still committed to selling this business to Apotekstjänst Sverige AB, but at the same time, we are also considering other options if we receive a negative verdict from the appeals. But we will be exiting the Swedish dose dispensing business because we still see that the tender market structure and dynamics in Sweden haven't changed. With this, I will then turn over to Mats and the financial view. So, welcome Mats.